Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain

Clinical Drug Investigation

Volumn 32, Issue SUPPL. 1, 2012, Pages 53-63

  Labianca, Roberto ^a   Sarzi Puttini, Piercarlo ^b   Zuccaro, Stefano Maria ^c   Cherubino, Paolo ^d   Vellucci, Renato ^e   Fornasari, Diego ^f  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Piazza San Bartolomeo All'Isola 21   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISACODYL; CETIRIZINE; CYCLOOXYGENASE 2 INHIBITOR; DIPHENHYDRAMINE; DOCUSATE SODIUM; FEXOFENADINE; GRANISETRON; HALOPERIDOL; HYDROXYZINE; ISPAGULA; LACTULOSE; LORATADINE; MACROGOL; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; MECLOZINE; METHYLCELLULOSE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE; PARACETAMOL; POLYCARBOPHIL; PROCHLORPERAZINE; PROMETHAZINE; PROSTAGLANDIN SYNTHASE INHIBITOR; SODIUM DIHYDROGEN PHOSPHATE; SORBITOL; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

AWARENESS; CHRONIC PAIN; CLINICAL PRACTICE; COGNITIVE DEFECT; CONSTIPATION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; NAUSEA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PRURITUS; REVIEW; RISK FACTOR; SOMNOLENCE; URINE RETENTION; VOMITING; XEROSTOMIA; SEVERITY OF ILLNESS INDEX; STANDARDS;

ANALGESICS, OPIOID; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC PAIN; CYCLOOXYGENASE INHIBITORS; HUMANS; PAIN MANAGEMENT; TREATMENT OUTCOME; ACETAMINOPHEN; ANALGESICS; PATIENT EDUCATION AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; SEVERITY OF ILLNESS INDEX;

EID: 84857510335     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11630080-000000000-00000     Document Type: Review

References (86)

1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333
2. Catala E, Reig E, Artes M, et al. Prevalence of pain in the Spanish population: telephone survey in 5000 homes. Eur J Pain 2002;6(2):133-40
3. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18(9):1437-49 (Pubitemid 47365475)
4. Katz WA. Musculoskeletal pain and its socioeconomic implications. Clin Rheumatol 2002;21 Suppl. 1:S2-4 (Pubitemid 34248140)
5. Ripamonti CI, Bandieri E, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22 Suppl. 6:vi69-77
6. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64(5):669-81 (Pubitemid 40559291)
7. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10(2):127-35 (Pubitemid 41727763)
8. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; (3): CD004847
9. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80 (Pubitemid 39550738)
10. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; (1): CD006605
11. Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003;74(2):102-12 (Pubitemid 36951807)
12. Blower AL, Brooks A, Fenn GC, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11(2):283-91 (Pubitemid 27183505)
13. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010;112(4):810-33
14. Institute for Clinical Systems Improvement. Health care guideline: Assessment and management of acute pain. [Online] 2008; Available from: http://www.icsi.org/pain-acute/pain-acute-assessment-and-management-of-3.html
15. Raffa RB, Stone Jr DJ, Tallarida RJ. Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine. Eur J Pharmacol 2001;412(2):R1-2 (Pubitemid 32124866)
16. Chou R, Qaseem A, Snow V, et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007;147(7):478-91 (Pubitemid 351688341)
17. Chun LJ, Tong MJ, Busuttil RW, et al. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol 2009;43(4):342-9
18. Stirnimann G, Kessebohm K, Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly; 140:w13080
19. Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007;26(2):283-90 (Pubitemid 46985498)
20. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006;296(1):87-93
21. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A metaanalysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901-7 (Pubitemid 38961912)
22. Lewis SC, Langman MJ, Laporte JR, et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002;54(3):320-6
23. Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal antiinflammatory drugs for low back pain. Cochrane Database Syst Rev 2008; (1): CD000396
24. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115(10):787-96
25. Garcia Rodriguez LA. Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs. Am J Med 1998;104(3A):30S-4S; discussion 41S-2S (Pubitemid 28186992)
26. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29(4):804-12 (Pubitemid 34303877)
27. Richy F, Bruyere O, Ethgen O, et al. Time dependent risk of gastrointestinal complications induced bynon-steroidal antiinflammatory drug use: a consensus statement using a metaanalytic approach. Ann Rheum Dis 2004;63(7):759-66 (Pubitemid 38850444)
28. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004;329(7472):948
29. Capurso L, Koch M. Prevention of NSAID-induced gastric lesions: H2 antagonists or misoprostol? A meta-analysis of controlled clinical studies. Clin Ter 1991;139(5-6):179-89
30. Leandro G, Pilotto A, Franceschi M, et al. Prevention of acute NSAID-related gastroduodenal damage: a metaanalysis of controlled clinical trials. Dig Dis Sci 2001;46(9):1924-36 (Pubitemid 32844159)
31. Rostom A, Wells G, Tugwell P, et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: a Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol 2000;27(9):2203-14
32. Shield MJ. Diclofenac/misoprostol: novel findings and their clinical potential. J Rheumatol Suppl 1998;51:31-41 (Pubitemid 28210540)
33. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120(3):594-606 (Pubitemid 32171634)
34. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359(9300):14-22 (Pubitemid 34119190)
35. Scheiman JM. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 2006;66 Suppl. 1:15-21; discussion 9-33
36. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340(24):1888-99 (Pubitemid 29272670)
37. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89(6A):3D-9D (Pubitemid 34241482)
38. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325(7365):619
39. Goldstein JL, Eisen GM, Burke TA, et al. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 2002;16(4):819-27 (Pubitemid 34407532)
40. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284(10):1247-55
41. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365(9458):475-81 (Pubitemid 40215729)
42. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142(7):481-9
43. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360(9339):1071-3
44. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109(17):2068-73 (Pubitemid 38620213)
45. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113(25):2906-13 (Pubitemid 44297231)
46. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44 (Pubitemid 44511610)
47. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364(9450):2021-9 (Pubitemid 39593078)
48. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21(1):1-15 (Pubitemid 32238607)
49. Harris RC, Breyer MD. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 2006;1(2):236-45
50. Large RG, Schug SA. Opioids for chronic pain of nonmalignant origin-caring or crippling. Health Care Anal 1995;3(1):5-11
51. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85(6):2215-22 (Pubitemid 32269246)
52. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349(20):1943-53 (Pubitemid 37409712)
53. Moulton D. "Hillbilly heroin" arrives in Cape Breton. CMAJ 2003;168(9):1172
54. Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7(5):381-6 (Pubitemid 37101777)
55. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005;7(5):R1046-51
56. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19(9):2542-54 (Pubitemid 32391226)
57. Swegle JM, Logemann C. Management of common opioidinduced adverse effects. Am Fam Physician 2006;74(8):1347-54 (Pubitemid 44607306)
58. Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain. J Pain Symptom Manage 2007;33(1):67-77 (Pubitemid 46017078)
59. Tassinari D, Sartori S, Tamburini E, et al. Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-analysis of randomized clinical trials. J Palliat Care 2009;25(3):172-80
60. Diego L, Atayee R, Helmons P, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs 2011;20(8):1047-56
61. ®) [database on the Internet]. National Cancer Institute. [cited 14 April 2011]. Available from: http://www.cancer.gov/ cancertopics/pdq/supportivecare/pain/HealthProfessional/Page3#Section-169
62. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350(24):2441-51
63. Ashby MA, Martin P, Jackson KA. Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust 1999;170(2):68-71 (Pubitemid 29037676)
64. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10(5):378-84
65. Vigano A, Fan D, Bruera E. Individualized use ofmethadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996;67(1):115-19 (Pubitemid 26319643)
66. Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998;16(2):121-4 (Pubitemid 28400162)
67. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4(5):231-56 (Pubitemid 36807905)
68. Bruera E, Franco JJ, Maltoni M, et al. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10(4):287-91
69. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989;36(2):169-76 (Pubitemid 19045575)
70. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manage 2003;26(5):1049-54 (Pubitemid 37324685)
71. Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996;51(5):713-37
72. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10(2):113-30
73. Heit HA. Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients. J Pain Palliat Care Pharmacother 2003;17(1):15-29 (Pubitemid 36438352)
74. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: a review. Int J Clin Pharmacol Ther 2004;42(4):191-203 (Pubitemid 38477435)
75. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009 Jul; 84(7):593-601
76. Kirsh KL, Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. Pain Med 2011 Jan; 12 Suppl 1:S1-11
77. Gotrick B, Akerman S, Ericson D, et al. Oral pilocarpine for treatment of opioid-induced oral dryness in healthy adults. J Dent Res 2004;83(5):393-7 (Pubitemid 41766095)
78. Wheeler M, Oderda GM, Ashburn MA, et al. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain 2002;3(3):159-80 (Pubitemid 34663605)
79. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl.):S105-20 (Pubitemid 351682081)
80. Rosow CE, Gomery P, Chen TY, et al. Reversal of opioidinduced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther 2007;82(1):48-53
81. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008;24(6):479-96
82. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001;61(15):2289-307 (Pubitemid 34074808)
83. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13(5):254-61 (Pubitemid 27240678)
84. Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322(7295):1154-8 (Pubitemid 32434223)
85. Parr G, Darekar B, Fletcher A, et al. Joint pain and quality of life; results of a randomised trial. Br J Clin Pharmacol 1989;27(2):235-42 (Pubitemid 19059487)
86. Sjogren P, Olsen AK, Thomsen AB, et al. Neuropsychological performance in cancer patients: the role of oral opioids, pain and performance status. Pain 2000;86(3):237-45 (Pubitemid 30254264)